Cancer Family
Invasive Malignant Neoplasm
CI-CAN-00000213Explore in graph →
604 active trials9 approved drugs37 evidence items
- NCIt
- C8505
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000213Explore in graph →
Clinical trials
1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Oct 3, 2022 |
| clinicaltrials |
| NCT03128619 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer | terminated | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer | terminated | Phase 1 | 15 | Shanghai East HospitalOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-01) | terminated | Phase 1 / Phase 2 | 13 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | terminated | Phase 1 | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | terminated | Phase 1 | 6 | George Washington UniversityOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | terminated | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 98 | Verastem, Inc.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | terminated | Phase 1 / Phase 2 | 2 | Georgetown UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT02708511 | Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer | terminated | Phase 1 | 2 | Sanjiv Sam GambhirOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01494012 | Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00005067 | Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00512668 | Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Dec 20, 2022source: clinicaltrials